JPMorgan Upgrades Forbright to Overweight From Neutral, Adjusts Price Target to $22 From $23

Forbright, Inc. (FRBT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Forbright, Inc. Reports Second Quarter 2026 Results Net interest income increased to $63.1 million Net interest margin increased to 3.19% Total loans grew to $6.1 billion Total deposits rose to $7.3 billion Credit trends remained favorable FOR IMMEDIATE RELEASE — CHE

Scotiabank upgraded Okta to Outperform ($165) and Datadog’s peer set (SentinelOne, Qualys, Tenable, Check Point) to Outperform; BofA upgraded T-Mobile to Buy ($220); HSBC upgraded Gilead to Buy ($155) and downgraded Allstate to Hold ($264) and Chubb to Hold. Bernstein downgraded Datadog to Market Perform ($226). Multiple other analyst rating changes and new coverages were issued across airlines, banks, retail, and energy.

Brookfield and Oaktree closed the Oaktree Asset-Backed Finance Fund (ABF I) at $2 billion, meeting its target. The fund attracted institutional investors and focuses on asset-backed finance across various sectors. ABF I leverages Brookfield's global scale and Oaktree's experience, building on their partnership since 2019. Brookfield's asset-based finance platform totals over $60 billion.

JPMorgan upgraded First Hawaiian (FHB) to Neutral, lowering its price target to $29.00. The bank's floating-rate loans and low deposit costs position it well in a higher rate environment. First Hawaiian reported better-than-expected Q2 2026 earnings and revenue, with improved net interest income and margin. The bank expects 3-4% loan growth and is progressing with merger plans with TriCo Bancshares.

TD Cowen initiated coverage on Teva Pharmaceutical (TEVA) with a buy rating and $55 price target, citing its pipeline and growth prospects. TEVA is near its 52-week high and has returned 98% over the past year. The FDA accepted Teva's NDA for ecopipam, and Moody's upgraded the company to investment grade. Other analysts also see growth potential in Teva's products.

JGC and Fluor received a Notice to Proceed for Phase 2 expansion of LNG Canada. JGC's $7.5B share will be recognized in fiscal 2026. LNG Canada, a JV including Shell, made the final investment decision. Phase 1 was completed in 2025, with Phase 2 expanding Canada's LNG export capacity.